UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of 

the Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported) February 26, 2018 (February 21, 2018) 

Merck & Co., Inc. 

(Exact Name of Registrant as Specified in Its Charter) 

New Jersey 

(State or Other Jurisdiction of Incorporation) 

  1-6571       22-1918501   

  (Commission File Number)       (I.R.S. Employer Identification No.)     

  2000 Galloping Hill Road, Kenilworth, NJ       07033   

  (Address of Principal Executive Offices)       (Zip Code)     

Registrant’s Telephone Number, Including Area Code (908) 740-4000 

Not Applicable 

(Former Name or Former Address, if Changed Since Last Report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter). 

o Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

(b) On February 21, 2018, Michael J. Holston, Executive Vice President and General Counsel of Merck & Co., Inc. (“Merck” or the “Company”), notified the Company that he will resign from his position with the Company effective April 1, 2018. Mr. Holston will accept an offer from General Electric Company to serve as the Senior Vice President, General Counsel and Secretary. 

2 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED] 

3